Feb 15, 2023
CHOSA has submitted an abstract presenting data on the first predictive biomarker for cisplatin and LiPlaCis in metastatic breast cancer to ASCO. The CHOSA team will participate in the ASCO conference as part of its business development efforts and engage in meetings with interested parties.
Heavily pretreated late-stage breast cancer patients of any subtype represent a huge treatment challenge. Cisplatin may work in selected patients but is often disqualified because of toxicity. LiPlaCis® is a liposomal formulation of cisplatin in development utilizing the sPLA2-triggered targeted release of cisplatin directly at the tumor. The prediction of cisplatin efficacy with a 205 mRNA profile has previously been demonstrated in a retrospective study in two Non-Small-Cell Lung Cancer (NSCLC) patient cohorts receiving adjuvant cisplatin1.
Now an abstract with prospective, blinded phase IIb data from the iCIP study has been submitted to ASCO and will be the backbone in discussions with potential partners at the ASCO conference.
The ASCO (American Society of Clinical Oncology) conference the largest cancer conference is held on June 2-6 in Chicago, USA.